2020 | Mammakarzinom | OriginalPaper | Buchkapitel
Erschienen in:
Therapiehandbuch Gynäkologie und Geburtshilfe
Damit für die am Mammakarzinom erkrankte Patientin die optimale Therapieentscheidung getroffen werden kann, ist es zunächst wichtig, das Mammakarzinom als systemische Erkrankung zu verstehen. Hierdurch werden auch die Therapieziele (Therapie des lokalen Tumors, Verhinderung von Rezidiv und Fernmetastasen) klar.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:
Anzeige
Zurück zum Zitat Baselga J, Bradbury I, Eidtmann H (2012) First results of the NeoaLTTO trial (BIG 01-06/EGF 106903): lapatinib with Trastuzumab for HER2-positive early breast cancer (NeoaLTTO): a randomized open label multicenter phase 3 trial. Lancet 379(9816):633–640 CrossRef Baselga J, Bradbury I, Eidtmann H (2012) First results of the NeoaLTTO trial (BIG 01-06/EGF 106903): lapatinib with Trastuzumab for HER2-positive early breast cancer (NeoaLTTO): a randomized open label multicenter phase 3 trial. Lancet 379(9816):633–640
CrossRef
Zurück zum Zitat Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 24(13):2019–2027 CrossRef Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 24(13):2019–2027
CrossRef
Zurück zum Zitat Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE et al (2012) Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol 30(7):709–717 CrossRef Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE et al (2012) Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol 30(7):709–717
CrossRef
Zurück zum Zitat Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 353(8):793–802. http://www.nejm.org/doi/abs/10.1056/NEJMoa050434 Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 353(8):793–802.
http://www.nejm.org/doi/abs/10.1056/NEJMoa050434
Zurück zum Zitat Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, et al (2018) Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 37(5):423–438. https://doi.org/10.1200/JCO.18.01160 Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, et al (2018) Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 37(5):423–438.
https://doi.org/10.1200/JCO.18.01160
Zurück zum Zitat Buus R, Sestak I, Kronenwett R, Denkert C, Dubsky P, Krappmann K et al (2016) Comparison of endopredict and epclin with oncotype dx recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst 108(11):djw149 CrossRef Buus R, Sestak I, Kronenwett R, Denkert C, Dubsky P, Krappmann K et al (2016) Comparison of endopredict and epclin with oncotype dx recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst 108(11):djw149
CrossRef
Zurück zum Zitat Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al (2016) 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375(8):717–729. http://www.nejm.org/doi/10.1056/NEJMoa1602253 Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al (2016) 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375(8):717–729.
http://www.nejm.org/doi/10.1056/NEJMoa1602253
Zurück zum Zitat Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia. J Clin Oncol 21(8):1431–1439 CrossRef Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia. J Clin Oncol 21(8):1431–1439
CrossRef
Zurück zum Zitat Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E et al (2014) Adjuvant zoledronic acid in patients with early breast cancer: Final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 15(9):997–1006 CrossRef Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E et al (2014) Adjuvant zoledronic acid in patients with early breast cancer: Final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 15(9):997–1006
CrossRef
Zurück zum Zitat Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372(5):436–446. http://www.nejm.org/doi/10.1056/NEJMoa1412379 Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372(5):436–446.
http://www.nejm.org/doi/10.1056/NEJMoa1412379
Zurück zum Zitat De Laurentiis M, Cancello G, D’Agostino D, Giuliano M, Giordano A, Montagna E, et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26(1):44–53. http://www.ncbi.nlm.nih.gov/pubmed/18165639 De Laurentiis M, Cancello G, D’Agostino D, Giuliano M, Giordano A, Montagna E, et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26(1):44–53.
http://www.ncbi.nlm.nih.gov/pubmed/18165639
Zurück zum Zitat Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, et al (2015) Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet 385(9980):1863–1872. http://www.ncbi.nlm.nih.gov/pubmed/25740286 Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, et al (2015) Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet 385(9980):1863–1872.
http://www.ncbi.nlm.nih.gov/pubmed/25740286
Zurück zum Zitat Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, et al (2018) Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet 385(9980):1863–1872. https://www.sciencedirect.com/science/article/pii/s0140673614620481 ([Internet] 2015 May 9 [cited 2018 Feb 21]) Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, et al (2018) Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet 385(9980):1863–1872.
https://www.sciencedirect.com/science/article/pii/s0140673614620481 ([Internet] 2015 May 9 [cited 2018 Feb 21])
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717 CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717
CrossRef
Zurück zum Zitat EBCTCG (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 379(9814):432–444. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273723/ EBCTCG (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 379(9814):432–444.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273723/
Zurück zum Zitat Eiermann W, Pienkowski T, Crown J, Chap L, Pawlicki M, Martin M, et al (2009) BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC → T) in women with Her-2/neu negative axillary lymph node positive early breast cancer. Cancer Res 69(2):77. http://cancerres.aacrjournals.org/content/69/2_Supplement/77.abstract Eiermann W, Pienkowski T, Crown J, Chap L, Pawlicki M, Martin M, et al (2009) BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC → T) in women with Her-2/neu negative axillary lymph node positive early breast cancer. Cancer Res 69(2):77.
http://cancerres.aacrjournals.org/content/69/2_Supplement/77.abstract
Zurück zum Zitat Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher E et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16(8):2672–2685 CrossRef Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher E et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16(8):2672–2685
CrossRef
Zurück zum Zitat Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25–32 CrossRef Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25–32
CrossRef
Zurück zum Zitat Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B et al (2013a) Personalizing the treatment of women with early breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013. Ann Oncol 24(9):2206–2223 CrossRef Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B et al (2013a) Personalizing the treatment of women with early breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013. Ann Oncol 24(9):2206–2223
CrossRef
Zurück zum Zitat Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, De Azambuja E, Procter M, Suter TM et al (2013b) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897):1021–1028 CrossRef Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, De Azambuja E, Procter M, Suter TM et al (2013b) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897):1021–1028
CrossRef
Zurück zum Zitat Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375(3):209–219. http://www.nejm.org/doi/10.1056/NEJMoa1604700 Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375(3):209–219.
http://www.nejm.org/doi/10.1056/NEJMoa1604700
Zurück zum Zitat Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, et al (2013) Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 – a randomized controlled phase III trial. J Clin Oncol 31(11):1398–1404. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612593/ Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, et al (2013) Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 – a randomized controlled phase III trial. J Clin Oncol 31(11):1398–1404.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612593/
Zurück zum Zitat Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M et al (2016a) West German study group phase III planB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 34(20):2341–2349 CrossRef Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M et al (2016a) West German study group phase III planB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 34(20):2341–2349
CrossRef
Zurück zum Zitat Gluz O, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates RE, Kreipe HH et al (2016b) Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Ann Oncol 27(6):1035–1040 CrossRef Gluz O, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates RE, Kreipe HH et al (2016b) Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Ann Oncol 27(6):1035–1040
CrossRef
Zurück zum Zitat Gray R (EBCTCG) et al (2018) Extended aromatase inhibitor treatment following 5 or more years of endocrine therapy: a metaanalysis of 22192 women in 11 randomised trials. SABCS GS3-03 Gray R (EBCTCG) et al (2018) Extended aromatase inhibitor treatment following 5 or more years of endocrine therapy: a metaanalysis of 22192 women in 11 randomised trials. SABCS GS3-03
Zurück zum Zitat Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6):976–983 CrossRef Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6):976–983
CrossRef
Zurück zum Zitat Huober J, Von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM et al (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124(1):133–140 CrossRef Huober J, Von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM et al (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124(1):133–140
CrossRef
Zurück zum Zitat L in EBCOG (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369(9574):1711–1723. http://www.sciencedirect.com/science/article/pii/s0140673607607788 L in EBCOG (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369(9574):1711–1723.
http://www.sciencedirect.com/science/article/pii/s0140673607607788
Zurück zum Zitat Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, Mclntyre KJ et al (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735. J Clin Oncol 27(8):1177–1183 CrossRef Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, Mclntyre KJ et al (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735. J Clin Oncol 27(8):1177–1183
CrossRef
Zurück zum Zitat Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R et al (2009) Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol 27(34):5685–5692 CrossRef Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R et al (2009) Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol 27(34):5685–5692
CrossRef
Zurück zum Zitat Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484):455–462 CrossRef Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484):455–462
CrossRef
Zurück zum Zitat Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I et al (2007) Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 25(19):2664–2670 CrossRef Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I et al (2007) Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 25(19):2664–2670
CrossRef
Zurück zum Zitat Liedtke C, Jackisch C, Thill M, Thomssen C, Müller V, Janni W, AGO Breast Committee (2018) AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2018. Breast Care 13:196–208. https://doi.org/10.1159/000489329 CrossRefPubMedPubMedCentral Liedtke C, Jackisch C, Thill M, Thomssen C, Müller V, Janni W, AGO Breast Committee (2018) AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2018. Breast Care 13:196–208.
https://doi.org/10.1159/000489329
CrossRefPubMedPubMedCentral
Zurück zum Zitat Love RR, Duc NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL et al (2003) HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 21(3):453–457 CrossRef Love RR, Duc NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL et al (2003) HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 21(3):453–457
CrossRef
Zurück zum Zitat Martín M, Seguí MA, Antón A, Ruiz A, Ramos M, Adrover E, et al (2010) Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. N Engl J Med 363(23):2200–2210. http://www.nejm.org/doi/abs/10.1056/NEJMoa0910320 Martín M, Seguí MA, Antón A, Ruiz A, Ramos M, Adrover E, et al (2010) Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. N Engl J Med 363(23):2200–2210.
http://www.nejm.org/doi/abs/10.1056/NEJMoa0910320
Zurück zum Zitat Moebus V, Jackisch C, Lueck HJ, Du Bois A, Thomssen C, Kurbacher C et al (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28(17):2874–2888 CrossRef Moebus V, Jackisch C, Lueck HJ, Du Bois A, Thomssen C, Kurbacher C et al (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28(17):2874–2888
CrossRef
Zurück zum Zitat Nitz U, Gluz O, Christgen M, Grischke E-M, Augustin D, Kümmel S, et al (2016) Final analysis of WSG-ADAPT HER2+/HR- trial: efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab ± weekly paclitaxel in HER2+/HR- early breast cancer (EBC). J Clin Oncol 34(15):518. http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.518 Nitz U, Gluz O, Christgen M, Grischke E-M, Augustin D, Kümmel S, et al (2016) Final analysis of WSG-ADAPT HER2+/HR- trial: efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab ± weekly paclitaxel in HER2+/HR- early breast cancer (EBC). J Clin Oncol 34(15):518.
http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.518
Zurück zum Zitat Perez E, Suman V, Davidson N, Gralow J, Kaufman P, Ingle J, et al (2010) Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of Trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. Cancer Res 69(24):80. https://cancerres.aacrjournals.org/content/69/24_Supplement/80.short Perez E, Suman V, Davidson N, Gralow J, Kaufman P, Ingle J, et al (2010) Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of Trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. Cancer Res 69(24):80.
https://cancerres.aacrjournals.org/content/69/24_Supplement/80.short
Zurück zum Zitat Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V et al (2015) Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat 151(2):251–259 CrossRef Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V et al (2015) Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat 151(2):251–259
CrossRef
Zurück zum Zitat Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672. https://www.nejm.org/doi/full/10.1056/nejmoa052306 Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672.
https://www.nejm.org/doi/full/10.1056/nejmoa052306
Zurück zum Zitat Rea D, Hasenburg A, Seynaeve C, Jones S, Vannetzel J, Paridaens R, et al (2009) Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancer. Cancer Res 69(24):11 LP-11. http://cancerres.aacrjournals.org/content/69/24_Supplement/11.abstract Rea D, Hasenburg A, Seynaeve C, Jones S, Vannetzel J, Paridaens R, et al (2009) Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancer. Cancer Res 69(24):11 LP-11.
http://cancerres.aacrjournals.org/content/69/24_Supplement/11.abstract
Zurück zum Zitat Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8 · 1 years median follow-up. Lancet Oncol 12(12):1101–1108 CrossRef Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8 · 1 years median follow-up. Lancet Oncol 12(12):1101–1108
CrossRef
Zurück zum Zitat Romond EH, Perez E, Bryant J, Suman VJ, Geyer CE, Davidson NE et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684 CrossRef Romond EH, Perez E, Bryant J, Suman VJ, Geyer CE, Davidson NE et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684
CrossRef
Zurück zum Zitat Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358(16):1663–1671. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18420499 Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358(16):1663–1671.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18420499
Zurück zum Zitat Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al (2015a) Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 373(21):2005–2014. http://www.nejm.org/doi/10.1056/NEJMoa1510764 Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al (2015a) Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 373(21):2005–2014.
http://www.nejm.org/doi/10.1056/NEJMoa1510764
Zurück zum Zitat Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, et al (2015b) Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. J Clin Oncol 33(21):2353–2360. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500829/ Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, et al (2015b) Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. J Clin Oncol 33(21):2353–2360.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500829/
Zurück zum Zitat Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. http://www.nejm.org/doi/abs/10.1056/NEJM200103153441101 Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792.
http://www.nejm.org/doi/abs/10.1056/NEJM200103153441101
Zurück zum Zitat Slamon D et al (2009) BCIRG 006 Phase 3 trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in the adjuvant treatment of HER2 – amplified e. Cancer Res Abstr 69(24 Suppl) Slamon D et al (2009) BCIRG 006 Phase 3 trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in the adjuvant treatment of HER2 – amplified e. Cancer Res Abstr 69(24 Suppl)
Zurück zum Zitat Spielmann M, Roché H, Delozier T, Canon J-L, Romieu G, Bourgeois H, et al (2009) Trastuzumab for patients with axillary-node – positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27(36):6129–6134. https://doi.org/10.1200/JCO.2009.23.0946 Spielmann M, Roché H, Delozier T, Canon J-L, Romieu G, Bourgeois H, et al (2009) Trastuzumab for patients with axillary-node – positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27(36):6129–6134.
https://doi.org/10.1200/JCO.2009.23.0946
Zurück zum Zitat Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast can. J Clin Oncol 23(31):7811–7819 CrossRef Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast can. J Clin Oncol 23(31):7811–7819
CrossRef
Zurück zum Zitat Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C et al (2016) Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol 17(3):345–356 CrossRef Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C et al (2016) Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol 17(3):345–356
CrossRef
Zurück zum Zitat Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M et al (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15(7):747–756 CrossRef Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M et al (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15(7):747–756
CrossRef
Zurück zum Zitat von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M et al (2018) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380(7):617–628 von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M et al (2018) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380(7):617–628
- Titel
- Adjuvante Therapie des Mammakarzinoms
- DOI
- https://doi.org/10.1007/978-3-662-59809-2_31
- Autoren:
-
Marie Tzschaschel
Jens Huober
- Verlag
- Springer Berlin Heidelberg
- Sequenznummer
- 31
- Kapitelnummer
- Kapitel 31